Single Telomere Length Analysis: An Independent Prognostic Marker for Cancer Patients

单端粒长度分析：癌症患者的独立预后标志

• 批准号: 133341
• 金额: $ 11.65万
• 依托单位: TELONOSTIX LTD.
• 依托单位国家: 英国
• 项目类别: Feasibility Studies
• 财政年份: 2018
• 资助国家: 英国
• 起止时间: 2018 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=133341
• 关键词: Single; Telomere; Length; Analysis; Independent

A case study for Innovate UK's Precision Medicine Catapult (PMC) (whose activities now fall under the Medicines Discvovery Catapult (MDC)), TeloNostiX Ltd's prognostic test for Chronic Lymphocytic Leukaemia (CLL) through Single Telomere Length Analysis (STELA) helps address two significant global healthcare challenges: 1) patient stratification and 2) precision medicine (a letter in support of the project from the PMC is available upon request). We seek funding to achieve two specific objectives critical to the development of our technology: (i) Demonstrate the technical feasibility of telomere testing in the routine clinical management of CLL patients by performing a logistical evaluation within an operational environment; (ii) Create a financial justification for NHS adoption of STELA by undertaking health economics modelling. The key focus will be to evaluate the potential for using STELA to stratify CLL patients into risk groups based on whether they will undergo clinical progression and require treatment. This analysis will consist of a literature review, evidence synthesis, and care pathway analysis. We will also engage with a global distributor of telomere tests and analyse the cancer prognostics market using current market reports to further quantify the business opportunity.

Innovate UK的精准医疗弹射器（PMC）案例研究TeloNostiX有限公司（其活动现在属于药物发现弹射器（MDC）），通过单个端粒长度分析（STELA）对慢性淋巴细胞白血病（CLL）的预后测试有助于解决两个重大的全球医疗保健挑战：1）患者分层和2）精准医疗（PMC支持该项目的信函可应要求提供）。我们寻求资金，以实现两个具体的目标，我们的技术的发展至关重要：（i）通过在操作环境中进行后勤评估，证明端粒检测在CLL患者的常规临床管理的技术可行性;（ii）通过进行卫生经济学建模，为NHS采用STELA创建财务理由。重点将是评估使用STELA将CLL患者分为风险组的可能性，基于他们是否会发生临床进展并需要治疗。该分析将包括文献综述、证据合成和护理路径分析。我们还将与端粒检测的全球分销商合作，并利用当前的市场报告分析癌症诊断市场，以进一步量化商机。